Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRETTO-432 adjuvant selpercatinib in RET fusion-positive NSCLC
jRCT2061210041Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Selpercatinib with Placebo (2 arms). Primary endpoint: Event-Free Survival. Started Dec 2021; status: active, not recruiting.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061210041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210041.